Drugs / CMV/AdV specific T cells
CMV/AdV specific T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00880789 | May 2009 → Aug 2013 | adenoviridae infectious disease, cytomegalovirus infection | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMV/AdV specific T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00880789 ↗ |
| Known as | Adenoviral/CMV-specific cytotoxic (killer) T-cells | “These cells have been trained to attack adenovirus/CMV-infected cells and are called Adenoviral/CMV-specific cytotoxic (killer) T-cells or "AdV/CMV-CTL."” NCT00880789 ↗ |
| Known as | AdV/CMV-CTL | “These cells have been trained to attack adenovirus/CMV-infected cells and are called Adenoviral/CMV-specific cytotoxic (killer) T-cells or "AdV/CMV-CTL."” NCT00880789 ↗ |
| Known as | CMV/AdV specific CTLs | “These cells are called "CMV/AdV specific CTLs" because they can attack those two viruses.” NCT00880789 ↗ |
| Action | Deplete | “This stimulation will train the T cells to kill cells with CMV and adenovirus on their surface.” NCT00880789 ↗ |
| Modality | Cell therapy | “These cells have been trained to attack adenovirus/CMV-infected cells and are called Adenoviral/CMV-specific cytotoxic (killer) T-cells or "AdV/CMV-CTL."” NCT00880789 ↗ |
| Route | Intravenous | “injected into the IV line” NCT00880789 ↗ |